Anti-fibrotic activity of Irbesartan in chronic hepatitis with hypertension using Elastography

Anti-fibrotic activity of Irbesartan in chronic hepatitis with hypertension using Elastography - Anti-fibrotic activity of Irbesartan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002707

Enrollment

Registered

2009-11-11

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis with hypertension

Interventions

Anti-fibrotic activity of Irbesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis BP 140/90 mmHg <=

Exclusion criteria

Exclusion criteria: 1. Patient is treated with RAS drugs prior to onset of this study. 2. Patient has a hepatocarcinoma. 3. Patient has a hypersensitivity to Irbesartan. 4. Patient is pregnant, or may become pregnant. 5. In the opinion of the investigator, patient is unsuitable as a study subject.

Design outcomes

Primary

Measure	Time frame
liver fibrosis	—

Countries

Japan

Contacts

Public ContactHiroyasu Morikawa

Graduate School of Medicine, Osaka City University Department of Hepatology

morikawa-h@med.osaka-cu.ac.jp06-6645-3801

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026